Request Trial
15 December 2024NewsAmericasChristopher Sweeney Executive Director Acuitas Therapeutics, Alison Maddeford Director Litigation & Risk Management Thermo Fisher Scientific, Daniel Yarbrough Head of Intellectual Property Element Biosciences, Madhuri Roy Partner Cooley

WATCH: The challenge of protecting patents and innovation - obviousness-type double patenting post In re Cellect

Speakers from Acuitas Therapeutics, Thermo Fisher Scientific, Element Biosciences, and Cooley examine the risks and implications of obviousness-type double patenting and offer guidance for mitigating its impact on innovation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
New rankings recognise top US patent firms and lawyers
13 February 2026   This year’s featured firms and individuals ranked by sister title WIPR, include those instructed on the biggest tech and life sciences cases, as well as the strategists devising global AI patent portfolios.
Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026   Telehealth platform faces legal action from the Danish pharma giant, as well as FDA pressure over GLP-1 drugs and a drop in shares after discontinuing new product.
Americas
Novartis takes aim at Tafinlar generic in latest suit
9 February 2026   The Swiss pharma giant moves to protect patents on its billion-dollar cancer therapy following an ANDA filing by a Canadian generics manufacturer.


Editor's picks

Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026

Editor's picks

Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026
Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026
Americas
Bayer enters COVID-19 vaccine row with three suits against major drugmakers
8 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025

More features

Hogan Lovells makes senior public and administrative hire in Italy
Danaher moves to acquire Masimo in $9.9bn deal
Generic rival blocked as AZ defends diabetes stronghold
Emotional Perception exclusive: ‘We are now very much open for business’
New rankings recognise top US patent firms and lawyers
Norton Rose Fulbright expands pharma and biotech disputes team
UPC appeals court confirms ‘all-or-nothing’ rule for unitary patents
Honigman bags second Kirkland litigator this year for IP team